Effect of Continuous Adductor Canal Block Versus Continuous Adductor Canal Block With Additional Infiltration Between The Popliteal Artery and Capsule of The Knee (IPACK) After Arthroscopic Knee Surgeries

Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age21-65
SponsorAin Shams University

About this trial

This study aims to evaluate the effect of Continuous Adductor Canal Block only versus adding posterior knee block, known as the Infiltration between the Popliteal Artery and Capsule of the Knee (IPACK) block with Continuous Adductor Canal Block (CACB) after arthroscopic knee surgeries.

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

Age from 21 to 65 years.

Both sexes.

American Society of Anesthesiologists (ASA) Physical Status Class I to II.

Patients with successful spinal anesthesia.

Disqualifiers

Declining to give written informed consent.

History of allergy to the medications used in the study.

Contraindications to regional anesthesia (including coagulopathy and local infection).

Polytrauma patients having lower limb fractures.

Trial design

Design model

Parallel

Treatments tested in this trial

  • Continuous adductor canal block

    Other intervention

    Patients will receive continuous adductor canal block.

  • Continuous Adductor Canal Block with additional Infiltration between The Popliteal Artery and Capsule

    Other intervention

    Patients will receive Continuous Adductor Canal Block with additional Infiltration between The Popliteal Artery and Capsule of The Knee

Treatment groups

70 Participants
are divided into 2 treatment groups
Group A: Group 1Experimental treatment 1 intervention
Group B: Group 2Experimental treatment 1 intervention

Trial outcomes

Primary outcomes

1

Degree of pain

The degree of pain will be assessed using the Visual Analogue Scale (VAS). VAS score is determined by measuring the distance (mm) on the 10-cm line between the "no pain" anchor and the patient's mark, providing a range of scores from 0-100. No pain (0-4 mm), mild pain (5-44 mm), moderate pain (45-74 mm), and severe pain (75-100 mm).

Time frame
24 hours postoperatively

Secondary outcomes

1

Total Nalbuphine consumption

Rescue analgesia will be given when VAS score ≥ 30 mm, in the form of IV injection of 10 mg Nalbuphine. Followed by reassessment of pain after 10 minutes, a second dose of Nalbuphine will be given if still VAS score ≥ 30 mm.

Time frame
24 hours postoperatively
2

Straight leg rise

Straight leg rise (SLR) will be recorded.

Time frame
24 hours postoperatively
3

Range of motion

Range of motion (ROM) will be recorded

Time frame
24 hours postoperatively
4

Rate of complications

Rate of complications like falling will be recorded

Time frame
24 hours postoperatively

Other outcomes

Sponsors and contacts

Click on the lead sponsor to view all of their trials.